A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections
- PMID:11486455
- DOI: 10.1046/j.1439-0507.2001.00632.x
A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections
Abstract
In a double-blind phase III study the efficacy and tolerance of eberconazole 1% cream was compared with clotrimazole 1% cream, applied twice daily for four consecutive weeks in 157 patients, with mycologically proven cutaneous candidosis (24 patients, 25 infected sites) and in 133 patients with dermatophyte skin infections (141 treated sites). The analysis was carried out by number of infected and treated sites. The four groups of sites and the distribution of target lesions were similar. The distribution of the sum of clinical scores and infecting organisms were also similar. There were no differences between the groups in terms of the range and mean duration of infection. At the end of therapy and on follow-up in skin candidosis the proportion of patients with effective treatment was 73 and 50% for clotrimazole and eberconazole, respectively. Premature termination due to adverse effects was 26.7% for clotrimazole and 20% for eberconazole. At the end of treatment of dermatophyte infections the proportion of patients with effective treatment was 46% for clotrimazole and 61% for eberconazole. At the overall assessment (6 weeks after the end of treatment) eberconazole was judged effective in 72% of treated sites, whereas clotrimazole was effective in 61%, this difference was not statistically significant (P = 0.15). There were three relapses (4%) in the clotrimazole-treated group and one relapse (1%) in the eberconazole group. One patient treated with eberconazole cream (1%) had a premature termination due to adverse events attributable to the medication.
Similar articles
- Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream.Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR.Repiso Montero T, et al.Int J Dermatol. 2006 May;45(5):600-4. doi: 10.1111/j.1365-4632.2006.02841.x.Int J Dermatol. 2006.PMID:16700802Clinical Trial.
- Topical treatment of dermatophytosis and cutaneous candidosis with flutrimazole 1% cream: double-blind, randomized comparative trial with ketoconazole 2% cream.del Palacio A, Cuétara S, Pérez A, Garau M, Calvo T, Sánchez-Alor G.del Palacio A, et al.Mycoses. 1999;42(11-12):649-55. doi: 10.1046/j.1439-0507.1999.00520.x.Mycoses. 1999.PMID:10680442Clinical Trial.
- Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis.de la Paz Cota BR, Cepero Vega PP, Matus Navarrete JJ, Aguado Mulgado GE, Narváez Huerta JJ, Lamadrid Bautista E, Fiscal Chauteco E.de la Paz Cota BR, et al.Am J Otolaryngol. 2018 May-Jun;39(3):307-312. doi: 10.1016/j.amjoto.2018.03.017. Epub 2018 Mar 6.Am J Otolaryngol. 2018.PMID:29551350Clinical Trial.
- Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.Croxtall JD, Plosker GL.Croxtall JD, et al.Drugs. 2009;69(3):339-59. doi: 10.2165/00003495-200969030-00009.Drugs. 2009.PMID:19275277Review.
- Topical fenticonazole in dermatology and gynaecology: current role in therapy.Veraldi S, Milani R.Veraldi S, et al.Drugs. 2008;68(15):2183-94. doi: 10.2165/00003495-200868150-00007.Drugs. 2008.PMID:18840006Review.
Cited by
- Topical antifungal treatments for tinea cruris and tinea corporis.El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, Moore M, Little P.El-Gohary M, et al.Cochrane Database Syst Rev. 2014 Aug 4;2014(8):CD009992. doi: 10.1002/14651858.CD009992.pub2.Cochrane Database Syst Rev. 2014.PMID:25090020Free PMC article.Review.
- Topical treatments for fungal infections of the skin and nails of the foot.Crawford F, Hollis S.Crawford F, et al.Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD001434. doi: 10.1002/14651858.CD001434.pub2.Cochrane Database Syst Rev. 2007.PMID:17636672Free PMC article.Review.
- Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris.Choudhary SV, Aghi T, Bisati S.Choudhary SV, et al.Indian Dermatol Online J. 2014 Apr;5(2):128-31. doi: 10.4103/2229-5178.131079.Indian Dermatol Online J. 2014.PMID:24860743Free PMC article.
- A Comparative Study of Efficacy and Safety of Eberconazole versus Terbinafine in Patients of Tinea Versicolor.Sharma J, Kaushal J, Aggarwal K.Sharma J, et al.Indian J Dermatol. 2018 Jan-Feb;63(1):53-56. doi: 10.4103/ijd.IJD_126_17.Indian J Dermatol. 2018.PMID:29527026Free PMC article.
- In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.Fernández-Torres B, Inza I, Guarro J.Fernández-Torres B, et al.J Clin Microbiol. 2003 Nov;41(11):5209-11. doi: 10.1128/JCM.41.11.5209-5211.2003.J Clin Microbiol. 2003.PMID:14605165Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical